Evidence map›Paper›PMID 31037648›Full record

ArticleMolecular neurobiology2019

Cholinergic Differentiation of Human Neuroblastoma SH-SY5Y Cell Line and Its Potential Use as an In vitro Model for Alzheimer's Disease Studies.

Liana M de Medeiros, Marco A De Bastiani, Eduardo P Rico, Patrícia Schonhofen, Bianca Pfaffenseller, Bianca Wollenhaupt-Aguiar, Lucas Grun, Florência Barbé-Tuana, Eduardo R Zimmer, Mauro A A Castro and 2 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed, 2 pooled it
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

130 citing papers in PubMed, 2 syntheses or guidelines pooled it, 233 citations in OpenAlex.

  1. Pooled it
  2. The cellular model for Alzheimer's disease research: PC12 cells.Frontiers in molecular neuroscience · 2022
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

Liana M de MedeirosLaboratory of Cellular Biochemistry, Department of Biochemistry, ICBS/UFRGS, 2600 Ramiro Barcelos St, Porto Alegre, RS, 90035-003, Brazil.
Marco A De BastianiLaboratory of Cellular Biochemistry, Department of Biochemistry, ICBS/UFRGS, 2600 Ramiro Barcelos St, Porto Alegre, RS, 90035-003, Brazil.
Eduardo P RicoPrograma de Pós-Graduação em Ciências da Saúde, Unidade Acadêmica de Ciências da Saúde, Universidade do Extremo Sul Catarinense (UNESC), Criciúma, SC, 88806-000, Brazil.
Patrícia SchonhofenLaboratory of Cellular Biochemistry, Department of Biochemistry, ICBS/UFRGS, 2600 Ramiro Barcelos St, Porto Alegre, RS, 90035-003, Brazil.
Bianca PfaffensellerLaboratory of Cellular Biochemistry, Department of Biochemistry, ICBS/UFRGS, 2600 Ramiro Barcelos St, Porto Alegre, RS, 90035-003, Brazil.
Bianca Wollenhaupt-AguiarLaboratory of Cellular Biochemistry, Department of Biochemistry, ICBS/UFRGS, 2600 Ramiro Barcelos St, Porto Alegre, RS, 90035-003, Brazil.
Lucas GrunPost-Graduate Program in Biochemistry, Department of Biochemistry, ICBS/UFRGS, Porto Alegre, RS, 90035-003, Brazil.
Florência Barbé-TuanaPost-Graduate Program in Biochemistry, Department of Biochemistry, ICBS/UFRGS, Porto Alegre, RS, 90035-003, Brazil.
Eduardo R ZimmerPost-Graduate Program in Biochemistry, Department of Biochemistry, ICBS/UFRGS, Porto Alegre, RS, 90035-003, Brazil.
Mauro A A CastroBioinformatics and Systems Biology Laboratory, Polytechnic Center, Federal University of Paraná (UFPR), Curitiba, PR, 81520-260, Brazil.
Richard B ParsonsSchool of Cancer and Pharmaceutical Sciences, King's College London, 150 Stamford Street, London, SE1 9NH, UK.
Fábio KlamtLaboratory of Cellular Biochemistry, Department of Biochemistry, ICBS/UFRGS, 2600 Ramiro Barcelos St, Porto Alegre, RS, 90035-003, Brazil. fabio.klamt@ufrgs.br.
National Council for Scientific and Technological Development · BRUniversidade Federal do Rio Grande do Sul · BRKing's College London · GBMcMaster University · CAPontifícia Universidade Católica do Rio Grande do Sul · BRUniversidade do Extremo Sul Catarinense · BRUniversidade Federal do Paraná · BR

Funding

CNPq/MS/SCTIE/DECIT 466989/2014-8MCTI/CNPq INCT-TM/CAPES/FAPESP 465458/2014-9PRONEX/FAPERGS 16/2551-0000499-4
6 · The paper itself

Abstract

Cholinergic transmission is critical to high-order brain functions such as memory, learning, and attention. Alzheimer's disease (AD) is characterized by cognitive decline associated with a specific degeneration of cholinergic neurons. No effective treatment to prevent or reverse the symptoms is known. Part of this might be due to the lack of in vitro models that effectively mimic the relevant features of AD. Here, we describe the characterization of an AD in vitro model using the SH-SY5Y cell line. Exponentially growing cells were maintained in DMEM/F12 medium and differentiation was triggered by the combination of retinoic acid (RA) and BDNF. Both acetylcholinesterase (AChE) and choline acetyltransferase (ChAT) enzymatic activities and immunocontent were determined. For mimicking tau and amyloid-β pathology, RA + BDNF-differentiated cells were challenged with okadaic acid (OA) or soluble oligomers of amyloid-β (AβOs) and neurotoxicity was evaluated. RA + BDNF-induced differentiation resulted in remarkable neuronal morphology alterations characterized by increased neurite density. Enhanced expression and enzymatic activities of cholinergic markers were observed compared to RA-differentiation only. Combination of sublethal doses of AβOs and OA resulted in decreased neurite densities, an in vitro marker of synaptopathy. Challenging RA + BDNF-differentiated SH-SY5Y cells with the combination of sublethal doses of OA and AβO, without causing considerable decrease of cell viability, provides an in vitro model which mimics the early-stage pathophysiology of cholinergic neurons affected by AD.

Indexed as

Cell DifferentiationModels, BiologicalAlzheimer DiseaseBiomarkersBrain-Derived Neurotrophic FactorCell Line, TumorCholinergic NeuronsGene Expression RegulationHumansNeuritesNeuroblastomaSignal TransductionSynapsesTretinoinBiomarkersBrain-Derived Neurotrophic FactorTretinoinBDNFCholinergic neuronsRetinoic acidSH-SY5Y

Identifiers

PMID31037648
OpenAlexW2943149722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.